The company utilizes a patented aqueous midazolam formulation, which is specially designed for administration in the nose and does not have nasal irritation, and will ensure accurate dosing. This formulation will be available in a unit dose device, which contains one dose of either 2.5 mg, 3.75 mg or 5 mg of midazolam for adults or children. The patented device is always ready for use (no priming needed), it comes with one hand actuation and it operates in every position (horizontal, vertical, etc. and thus also in patients in horizontal position). The device is easy to carry and ensures a hygienic, simple and fast administration. Under- or overdosing is not possible. The product will be branded as Nazolam® or Nasolam®.